Vertex Pharmaceuticals Inc (VRTX)

85.73
NASDAQ : Health Care
Prev Close 85.73
Day Low/High 0.00 / 0.00
52 Wk Low/High 71.46 / 103.73
Avg Volume 1.86M
Exchange NASDAQ
Shares Outstanding 248.03M
Market Cap 21.28B
EPS -0.50
P/E Ratio 100.93
Div & Yield N.A. (N.A)

Latest News

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.

Vertex Reports Full-Year And Fourth-Quarter 2016 Financial Results

Vertex Reports Full-Year And Fourth-Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full-year and quarter-ended December 31, 2016.

Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research And Development Programs From Vertex

Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research And Development Programs From Vertex

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four promising...

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business

Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business

Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.

Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis

Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis

Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.

Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.

Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement

Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement

Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.

Vertex Provides Update On Business And Financial Performance And Research And Development Programs

Vertex Provides Update On Business And Financial Performance And Research And Development Programs

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its business performance, including preliminary financial results for 2016 and a financial outlook for 2017, and an update on its ongoing...

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2016 Financial Results

Vertex Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Vertex Announces German Reimbursement Agreement For ORKAMBI® (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Announces German Reimbursement Agreement For ORKAMBI® (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI ® (lumacaftor/ivacaftor) with the German Federal Association of the Statutory...

Vertex Pharmaceuticals Becomes #42 Most Shorted Nasdaq 100 Component, Replacing Cerner

Vertex Pharmaceuticals Becomes #42 Most Shorted Nasdaq 100 Component, Replacing Cerner

The most recent short interest data has been released for the 11/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Broadcom Call Should 'Make You Feel Better About Owning Apple': More Squawk From Jim Cramer

Broadcom Call Should 'Make You Feel Better About Owning Apple': More Squawk From Jim Cramer

Broadcom released better-than-expected 2016 fourth-quarter results, and its stock on Friday is giving a picture of where the rally could 'broaden to,' says Jim Cramer.

More Base Building Ahead for Vertex Pharmaceuticals

More Base Building Ahead for Vertex Pharmaceuticals

Buy signals have not lasted more than two months, so far.

Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

These stocks are down some 20% over the last 30 months and look ripe for a rise.

Positive Phase 3 Study Of ORKAMBI® In Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies Of The F508del Mutation Supports A Submission To The European Medicines Agency In The First Half Of 2017

Positive Phase 3 Study Of ORKAMBI® In Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies Of The F508del Mutation Supports A Submission To The European Medicines Agency In The First Half Of 2017

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced the results of a Phase 3 study of ORKAMBI ® (lumacaftor/ivacaftor) in children with cystic fibrosis (CF) ages 6 through 11 who have two copies of...

Vertex To Present At The Credit Suisse Healthcare Conference On November 8

Vertex To Present At The Credit Suisse Healthcare Conference On November 8

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8 th at 3:30 p.

Vertex Pharmaceuticals Enters Oversold Territory

Vertex Pharmaceuticals Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.